BlackRock’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-39,706
| Closed | -$52.4K | – | 5528 |
|
|
2024
Q3 | $52.4K | Buy |
39,706
+428
| +1% | +$2.07K | ﹤0.01% | 4808 |
|
|
2024
Q2 | $299K | Hold |
39,278
| – | – | ﹤0.01% | 4464 |
|
|
2024
Q1 | $354K | Sell |
39,278
-6
| -0% | -$53 | ﹤0.01% | 4467 |
|
|
2023
Q4 | $421K | Hold |
39,284
| – | – | ﹤0.01% | 4464 |
|
|
2023
Q3 | $236K | Sell |
39,284
-11
| -0% | -$77 | ﹤0.01% | 4633 |
|
|
2023
Q2 | $271K | Sell |
39,295
-6,273
| -14% | -$41.4K | ﹤0.01% | 4658 |
|
|
2023
Q1 | $715K | Sell |
45,568
-5,035
| -10% | -$99.1K | ﹤0.01% | 4441 |
|
|
2022
Q4 | $1.01M | Buy |
50,603
+901
| +2% | +$17.9K | ﹤0.01% | 4408 |
|
|
2022
Q3 | $887K | Sell |
49,702
-575
| -1% | -$12.3K | ﹤0.01% | 4521 |
|
|
2022
Q2 | $1.11M | Sell |
50,277
-105,544
| -68% | -$2.35M | ﹤0.01% | 4494 |
|
|
2022
Q1 | $4.33M | Sell |
155,821
-4,056
| -3% | -$148K | ﹤0.01% | 4044 |
|
|
2021
Q4 | $7.26M | Sell |
159,877
-83
| -0.1% | -$5.58K | ﹤0.01% | 3841 |
|
|
2021
Q3 | $13.3M | Sell |
159,960
-26
| -0% | -$2.15K | ﹤0.01% | 3537 |
|
|
2021
Q2 | $15.2M | Buy |
159,986
+106,203
| +197% | +$12.6M | ﹤0.01% | 3455 |
|
|
2021
Q1 | $8.95M | Buy |
53,783
+36,632
| +214% | +$4.84M | ﹤0.01% | 3641 |
|
|
2020
Q4 | $1.68M | Buy |
17,151
+13,915
| +430% | +$880K | ﹤0.01% | 4088 |
|
|
2020
Q3 | $110K | Sell |
3,236
-34
| -1% | -$1.67K | ﹤0.01% | 4495 |
|
|
2020
Q2 | $185K | Buy |
3,270
+1,509
| +86% | +$85.1K | ﹤0.01% | 4382 |
|
|
2020
Q1 | $103K | Hold |
1,761
| – | – | ﹤0.01% | 4347 |
|
|
2019
Q4 | $139K | Sell |
1,761
-145
| -8% | -$15K | ﹤0.01% | 4384 |
|
|
2019
Q3 | $191K | Buy |
1,906
+260
| +16% | +$26.6K | ﹤0.01% | 4333 |
|
|
2019
Q2 | $219K | Sell |
1,646
-1,608
| -49% | -$248K | ﹤0.01% | 4349 |
|
|
2019
Q1 | $547K | Sell |
3,254
-64
| -2% | -$9.54K | ﹤0.01% | 4078 |
|
|
2018
Q4 | $364K | Sell |
3,318
-115
| -3% | -$23K | ﹤0.01% | 4129 |
|
|
2018
Q3 | $755K | Buy |
3,433
+646
| +23% | +$1.55M | ﹤0.01% | 4025 |
|
|
2018
Q2 | $5.97M | Buy |
2,787
+1,572
| +129% | +$3.99M | ﹤0.01% | 3452 |
|
|
2018
Q1 | $3.02M | Sell |
1,215
-14
| -1% | -$31.2K | ﹤0.01% | 3571 |
|
|
2017
Q4 | $2.19M | Buy |
1,229
+10
| +0.8% | +$14.5K | ﹤0.01% | 3666 |
|
|
2017
Q3 | $1.44M | Buy |
1,219
+22
| +2% | +$19.8K | ﹤0.01% | 3793 |
|
|
2017
Q2 | $885K | Buy |
1,197
+79
| +7% | +$48.5K | ﹤0.01% | 3876 |
|
|
2017
Q1 | $767K | Buy |
+1,118
| New | +$819K | ﹤0.01% | 3862 |
|
|
2013
Q3 | – | Sell |
-1
| Closed | -$5K | – | 3116 |
|
|
2013
Q2 | $5K | Buy |
+1
| New | +$7.71K | ﹤0.01% | 3038 |
|
Other funds holding ONCT
BlackRock's ONCT Position: Q4 2024 in Review
BlackRock sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 39,706 shares — an estimated $52.4K sold.
BlackRock first reported a position in ONCT in Q2 2013 and held it in 32 quarters. The position peaked at $15.2M in Q2 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.
- BlackRock reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- BlackRock sold 39,706 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $52.4K.
- BlackRock first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 32 quarters.
- BlackRock's Oncternal Therapeutics, Inc. Common Stock position peaked at $15.2M in Q2 2021.
- 4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.
Based on BlackRock's 13F filing for Q4 2024, filed 7 Feb 2025.